StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Change in Fair Value of Contingent Consideration by Quarter

Change in Fair Value of Contingent Consideration — After-Tax ($M) ($M)

QuarterlyAnnual

AbbVie Change in Fair Value of Contingent Consideration: $1,479M in Q2 2026, down 45.4% from a year earlier.

Latest, Q2 2026
1,479
Period ended Jun 30, 2026
Change on a year earlier
-45.4%
2,709 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below

Where the Q2 2026 figure comes from

“|| Change in fair value of contingent consideration | 1,518 | 1,479 | 0.83”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Non-GAAP Reconciliations.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedChange in Fair Value of Contingent Consideration — After-Tax ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,479-45.4%Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20262,325+57.4%Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20251,368+404.8%Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025755-42.8%Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20252,709+88.4%Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20251,477+129.7%Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024271-83.6%Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20241,321+16,412.5%Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20241,438-5.3%Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024643-64.7%Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20231,655-21.7%Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20238-103.7%Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20231,518–Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20231,822–Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20222,113–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-218–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Change in Fair Value of Contingent Consideration ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-spec-cc-aftertax

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.